论文部分内容阅读
目的:血清和肽素、胱抑素C及CA125水平与心力衰竭新活素治疗效果的相关性探究。方法:收集2012年4月~2015年1月来我院就诊的心力衰竭患者168例,均给予新活素及常规心力衰竭治疗,有效患者133例,为有效组,无效患者35例,为无效组。观察两组患者血清和肽素、胱抑素C及CA125水平变化,探讨其水平变化与治疗效果的相关性。结果:血清和肽素、胱抑素C及CA125水平经Logistic回归分析,三组血清分子最大似然比估计值和OR值均<0,且具有统计学意义(P<0.05)。讨论:血清和肽素、胱抑素C及CA125水平与心力衰竭新活素治疗效果存在相关性并为负相关,血清水平越低,患者治疗效果越好。
Objective: To investigate the correlation between the levels of serum copeptin, cystatin C and CA125 levels and the therapeutic effect of neomycin in heart failure. Methods: A total of 168 patients with heart failure admitted to our hospital from April 2012 to January 2015 were enrolled in the new survivor and conventional heart failure treatment, 133 patients were effective, 35 patients were effective and 35 patients were ineffective group. To observe the changes of serum copeptin, cystatin C and CA125 levels in two groups of patients, and to explore the correlation between the level changes and the therapeutic effect. Results: The levels of serum copeptin, cystatin C and CA125 were analyzed by Logistic regression analysis. The maximum likelihood ratio (OR) and the maximum likelihood ratio (OR) between the three groups were all less than 0, with statistical significance (P <0.05). Discussion: Serum copeptin, cystatin C and CA125 levels and the new treatment of heart failure have a positive correlation between the effect and negative correlation, the lower the serum level, the better the treatment of patients.